Your browser doesn't support javascript.
loading
EczemaPred: A computational framework for personalised prediction of eczema severity dynamics.
Hurault, Guillem; Stalder, Jean François; Mery, Sophie; Delarue, Alain; Saint Aroman, Markéta; Josse, Gwendal; Tanaka, Reiko J.
Afiliación
  • Hurault G; Department of Bioengineering, Imperial College London, London, UK.
  • Stalder JF; Clinique Dermatologique University Hospital, Nantes, France.
  • Mery S; Pierre Fabre Laboratories, Toulouse, France.
  • Delarue A; Pierre Fabre Laboratories, Toulouse, France.
  • Saint Aroman M; Pierre Fabre Laboratories, Toulouse, France.
  • Josse G; Pierre Fabre Laboratories, Toulouse, France.
  • Tanaka RJ; Department of Bioengineering, Imperial College London, London, UK.
Clin Transl Allergy ; 12(3): e12140, 2022 Mar.
Article en En | MEDLINE | ID: mdl-35344305
ABSTRACT

BACKGROUND:

Atopic dermatitis (AD) is a chronic inflammatory skin disease leading to substantial quality of life impairment with heterogeneous treatment responses. People with AD would benefit from personalised treatment strategies, whose design requires predicting how AD severity evolves for each individual.

OBJECTIVE:

This study aims to develop a computational framework for personalised prediction of AD severity dynamics.

METHODS:

We introduced EczemaPred, a computational framework to predict patient-dependent dynamic evolution of AD severity using Bayesian state-space models that describe latent dynamics of AD severity items and how they are measured. We used EczemaPred to predict the dynamic evolution of validated patient-oriented scoring atopic dermatitis (PO-SCORAD) by combining predictions from the models for the nine severity items of PO-SCORAD (six intensity signs, extent of eczema, and two subjective symptoms). We validated this approach using longitudinal data from two independent studies a published clinical study in which PO-SCORAD was measured twice weekly for 347 AD patients over 17 weeks, and another one in which PO-SCORAD was recorded daily by 16 AD patients for 12 weeks.

RESULTS:

EczemaPred achieved good performance for personalised predictions of PO-SCORAD and its severity items daily to weekly. EczemaPred outperformed standard time-series forecasting models such as a mixed effect autoregressive model. The uncertainty in predicting PO-SCORAD was mainly attributed to that in predicting intensity signs (75% of the overall uncertainty).

CONCLUSIONS:

EczemaPred serves as a computational framework to make a personalised prediction of AD severity dynamics relevant to clinical practice. EczemaPred is available as an R package.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Idioma: En Revista: Clin Transl Allergy Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Idioma: En Revista: Clin Transl Allergy Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido